BioPharmSignal logoBioPharmSignal

Biotech News

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

MoonLake Immunotherapeutics (MLTX)MoonLake ImmunotherapeuticsFDA / regulatory

The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive results from the Phase 2 LEDA trial The upcoming Phase 3 program will therefore be expected to

Open original release

Related news

MLTXMoonLake Immunotherapeutics2026-05-10 13:00 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

KYMRKymera2026-04-13 11:00 EST

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

GRIGRI Bio2026-06-18 13:31 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

MLTXMoonLake Immunotherapeutics2026-03-28 19:00 EST

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

ARGXArgenx2026-05-08 21:20 EST

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

REGNRegeneron Pharmaceuticals2026-04-23 16:40 EST

Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.

ATYRaTyr Pharma2026-05-11 20:01 EST

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

REGNRegeneron Pharmaceuticals2026-04-22 21:30 EST

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

APLSApellis Pharmaceuticals2026-03-31 10:59 EST

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

View all latest news

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a biotechnology company focused on inflammatory skin and immune-mediated diseases. Its story is built around developing differentiated therapies for conditions like hidradenitis suppurativa and other inflammatory disorders.

Recent company news

MLTXMoonLake Immunotherapeutics2026-05-10 13:00 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

MLTXMoonLake Immunotherapeutics2026-03-28 19:00 EST

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

MLTXMoonLake Immunotherapeutics2026-02-22 16:00 EST

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

MLTXMoonLake Immunotherapeutics2026-02-02 13:00 EST

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

MLTXMoonLake Immunotherapeutics2026-01-08 13:00 EST

MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day

Stock data

Close
19.88 USD
Market cap
1.32B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States